Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children

Journal of Infection

Volumn 57, Issue 3, 2008, Pages 223-228

  Tamura, Akihiro ^a   Matsubara, Kousaku ^a   Tanaka, Takayuki ^a   Nigami, Hiroyuki ^a   Yura, Kazuo ^a   Fukaya, Takashi ^a  

^a NISHI KOBE MEDICAL CENTER   (Japan)

Author keywords

Children; Methylprednisolone; Mycoplasma pneumoniae; Pulse; Refractory

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA 2 MICROGLOBULIN; CEFOTIAM; CLARITHROMYCIN; CLINDAMYCIN; CORTICOSTEROID; ERYTHROMYCIN; FERRITIN; FLOMOXEF; LACTATE DEHYDROGENASE; MACROLIDE; METHYLPREDNISOLONE; MINOCYCLINE; PANIPENEM PLUS BETAMIPRON;

ABNORMAL LABORATORY RESULT; ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DETERIORATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG INFILTRATE; MALE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; PLEURA EFFUSION; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; RADIOGRAPHY, THORACIC; TREATMENT OUTCOME;

EID: 50449100763     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.06.012     Document Type: Article

References (20)

1. Bamba M., Jozaki K., Sugaya N., Tamai S., Ishihara J., Kori T., et al. Prospective surveillance for atypical pathogens in children with community-acquired pneumonia in Japan. J Infect Chemother 12 (2006) 36-41
2. Radisic M., Torn A., Gutierrez P., Defranchi H.A., and Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 31 (2000) 1507-1511
3. Wang R.S., Wang S.Y., Hsieh K.S., Chiou Y.H., Huang I.F., Cheng M.F., et al. Necrotizing pneumonitis caused by Mycoplasma pneumoniae in pediatric patients. Pediatr Infect Dis J 23 (2004) 564-567
4. Takiguchi Y., Shikama N., Aotsuka N., Koseki H., Terano T., and Hirai A. Fulminant Mycoplasma pneumoniae pneumonia. Intern Med 40 (2001) 345-348
5. Chan E.D., and Welsh C.H. Fulminant Mycoplasma pneumoniae pneumonia. West J Med 162 (1995) 133-142
6. Koletsky R.J., and Weinstein A.J. Fulminant Mycoplasma pneumoniae infection. Report of a fatal case and a review of the literature. Am Rev Respir Dis 122 (1980) 491-496
7. Fujishiro M., Takezawa S., Hasejima N., Kobayashi H., and Yamato K. A case of fulminant Mycoplasma pneumoniae pneumonia successfully treated by steroid therapy. Nihon Kokyuki Gakkai Zasshi 37 (1999) 476-480 [in Japanese with English abstract]
8. Miyashita N., Obase Y., Ouchi K., Kawasaki K., Kawai Y., Kobashi Y., et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 56 (2007) 1625-1629
9. Lee K.Y., Lee H.S., Hong J.H., Lee M.H., Lee J.S., Burgner D., et al. Role of prednisolone treatment in severe Mycoplasma pneumonia pneumonia in children. Pediatr Pulmonol 41 (2006) 263-268
10. Foy H.M., Ochs H., Davis S.D., Kenny G.E., and Luce R.R. Mycoplasma pneumoniae infections in patients with immunodeficiency syndromes: report of four cases. J Infect Dis 127 (1973) 388-393
11. Mizutani H., Kitayama T., Hayakawa A., and Nagayama E. Delayed hypersensitivity in Mycoplasma pneumoniae infection. Lancet 1 7691 (1971) 186-187
12. Tanaka H., Narita M., Teramoto S., Saikai T., Oashi K., Igarashi T., et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest 121 (2002) 1493-1497
13. Hsieh C.C., Tang R.B., Tsai C.H., and Chen W. Serum interleukin-6 and tumor necrosis factor-α concentrations in children with mycoplasma pneumonia. J Microbiol Immunol Infect 34 (2001) 109-112
14. Ishida Y., Hiroi K., Tauchi H., Oto Y., Tokuda K., and Kida K. Hemaphagocytic lymphohistiocytosis secondary to mycoplasma pneumoniae infection. Pediatr Int 46 (2004) 174-177
15. Ho J.C., Ooi G.C., Mok T.Y., Chan J.W., Hung I., Lam B., et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 168 (2003) 1449-1456
16. Carter M.J. A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 56 (2007) 875-883
17. Cimolai N. Corticosteroids and complicated Mycoplasma pneumoniae infection. Pediatr Pulmonol 41 (2006) 1008-1009
18. Matsuoka M., Narita M., Okazaki N., Ohya H., Yamazaki T., Ouchi K., et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 48 (2004) 4624-4630
19. Morozumi M., Hasegawa K., Kobayashi R., Inoue N., Iwata S., Kuroki H., et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother 49 (2005) 2302-2306
20. Suzuki S., Yamazaki T., Narita M., Okazaki N., Suzuki I., Andoh T., et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 50 (2006) 709-712